PCM
TRVI icon

Prelude Capital Management’s Trevi Therapeutics TRVI Stock Holding History

Prelude Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-49,937
Closed -$314K – 1364
2025
Q1 		$314K Buy
+49,937
New +$238K 0.02% 689

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Prelude Capital Management's TRVI Position: Q2 2025 in Review

Prelude Capital Management sold out of Trevi Therapeutics (TRVI) in Q2 2025, closing a stake of 49,937 shares — an estimated $314K sold.

Prelude Capital Management first reported a position in TRVI in Q1 2025 and held it in 1 quarter. The position peaked at $314K in Q1 2025. 153 funds tracked by Wall St. Rank hold TRVI as of Q2 2025.

  • Prelude Capital Management reported no remaining Trevi Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Prelude Capital Management sold 49,937 Trevi Therapeutics shares in Q2 2025, an estimated $314K.
  • Prelude Capital Management first reported a position in Trevi Therapeutics in Q1 2025 and held it in 1 quarter.
  • Prelude Capital Management's Trevi Therapeutics position peaked at $314K in Q1 2025.
  • 153 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2025.

Based on Prelude Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.